$2.68
4.28%
Nasdaq, Fri, Dec 27 2024
ISIN
CA0079754028
Symbol
AEZS
Sector
Industry

Aeterna Zentaris Inc. Stock price

$2.68
-0.42 13.43% 1M
-1.88 41.21% 6M
-4.77 64.05% YTD
-4.53 62.85% 1Y
-37.33 93.31% 3Y
-79.37 96.74% 5Y
-6,197.33 99.96% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.12 4.28%
ISIN
CA0079754028
Symbol
AEZS
Sector
Industry

Key metrics

Market capitalization $8.36m
Enterprise Value $-10.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.57
EV/Sales (TTM) EV/Sales -2.31
P/S ratio (TTM) P/S ratio 1.93
P/B ratio (TTM) P/B ratio 0.42
Revenue growth (TTM) Revenue growth -36.86%
Revenue (TTM) Revenue $4.33m
EBIT (operating result TTM) EBIT $-21.10m
Free Cash Flow (TTM) Free Cash Flow $-17.55m
Cash position $20.00m
EPS (TTM) EPS $-26.09
P/S forward 2.26
EV/Sales forward negative
Short interest 0.53%
Show more

Is Aeterna Zentaris Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Aeterna Zentaris Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aeterna Zentaris Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aeterna Zentaris Inc.:

Buy
100%

Financial data from Aeterna Zentaris Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4.33 4.33
37% 37%
100%
- Direct Costs 2.72 2.72
616% 616%
63%
1.62 1.62
75% 75%
37%
- Selling and Administrative Expenses 11 11
38% 38%
254%
- Research and Development Expense 11 11
24% 24%
249%
-20 -20
29% 29%
-465%
- Depreciation and Amortization 0.94 0.94
488% 488%
22%
EBIT (Operating Income) EBIT -21 -21
34% 34%
-487%
Net Profit -19 -19
21% 21%
-429%

In millions USD.

Don't miss a Thing! We will send you all news about Aeterna Zentaris Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aeterna Zentaris Inc. Stock News

Neutral
GlobeNewsWire
5 months ago
TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Compan...
Neutral
GlobeNewsWire
6 months ago
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business conside...

Company Profile

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Head office Canada
CEO Gilles Gagnon
Employees 21
Founded 1990
Website www.aeternazentaris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today